Tag Archives: GSK EPS Q3 2013

GlaxoSmithKline delivers Q3 core EPS of 28.9p (+16% CER) and dividend of 19p (+6%)

London, UK, 23-10-2013 — /EuropaWire/ — GSK announces Q3 core EPS growth of 16% and dividend of 19p Core EPS 28.9p (+16%) benefiting from operating, financial and long-term cost efficiencies Pharma & Vaccines sales flat: US +2%, Europe +5%, Japan +2% offset by … Read the full press release